drugset / Trial / NCT07168915

A Study of V118E in Healthy Participants (V118E-003)

NCT07168915

Phase 1 Recruiting 126 enrolled Merck Sharp & Dohme LLC
RandomizedSequentialDouble-blindPrevention

Summary

Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.

Timeline

Start
2025-10-08
Primary completion
2027-07-06
Completion
2027-07-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator PCV20 Vaccine Intramuscular
Subject V118E Vaccine Intramuscular

Indications

No indication recorded.